retatrutide triple hormone receptor agonist retatrutide Phase 2 Trial of Retatrutide

8 weeks (11 vials): 33 mL 4 10 mL bottles 12 weeks (17 vials): 51 mL 6 10 mL bottles 16 weeks (22 vials): 66 mL 7 10 mL bottles Alcohol Swabs: One for the vial stopper + one for the injection site each day

However, due to skyrocketing demand and intermittent shortages, compounding pharmacies have stepped in to provide patients with custom-formulated alternatives

Im optimistic on how the combination of an oral option plus market competition is going to mean access for more patients that want and would benefit from these medications

Not a researcher

Eli Lilly and Company Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

To view or add a comment, sign in Explore related topics Explore content categories